"The increasing prevalence of cervical cancer in middle-age women and subsequent increase in the number of screening and diagnostic tests is expected to boost cervical cancer diagnostic market over the forecast period"
The global cervical cancer diagnostic market was valued at USD 7 billion in 2015 and is projected to grow at a CAGR of 5.9% over the forecast period. Women between the age group of 20 and 60 years are usually more prone to this ailment, which is expected to increase the screening and diagnostics procedures of cervical cancer.
Cervical cancer is amongst one of the most common causes of deaths in the U.S. women. The U.S. has a very high prevalence of cervical cancer, which is a key driving force for growth of the market. According to the American Cancer Society, an estimated 12,990 new cases of invasive cervical cancer would be diagnosed and would cause death of 4,120 women in 2016. The death rate due to cervical cancer has dropped over the last 40 years by up to more than 50%, thus indicating the growing adoption of screening procedures, such as Pap test and HPV testing. In the U.S., Hispanic women are at a higher risk of developing cervical cancer followed by African-Americans, Pacific-Islanders, and white women. Alaskans and American Indians are expected to be at the lowest risk of developing it.
The presence of favorable policies related to reimbursement is another key factor anticipated to boost the number of screening tests over the forecast period. Additionally, technology is a key enabler of the improving access and affordability of various diagnostic tests across the U.S. The technological advancements in terms of new diagnostic equipment, diagnostic procedures, and screening techniques are expected to have a positive impact on the market as well. Some of the key biomarkers available are long noncoding RNAs (lncRNA), mRNA, m6A, etc. The increasing demand for the novel treatment and biomarkers in order to improve screening results is one of the pivotal factors driving the market.
"Pap testing accounted for the largest market share in 2015"
Pap test held a majority share of 49.6% of the segment in 2015. Pap test helps diagnose abnormal cells of the cervix that may potentially develop into cancer at a later stage. This test accounts for the largest share on account of the high efficiency of this test. Furthermore, the increasing awareness regarding early diagnosis contributes to the growth of this segment.
HPV testing is expected to grow at a lucrative CAGR of 15.3% due to the upsurge in the demand for technologically advanced diagnostics procedures at low costs and further developments in use of various biomarkers along with the regular screening procedures. Hence, the enhanced accuracy and sensitivity of the screening tests is one of the crucial factors anticipated to propel growth in the coming years.
"North America accounted for a share of 48.3% in the cervical cancer diagnostic market"
In 2015, North America accounted for the maximum revenue share of 48.3%, and is closely followed by Europe. The U.S. is the most important sector and captured the majority share of the North American segment. The growing prevalence of cervical cancer in the region and increasing awareness regarding early diagnosis can be attributed to the large share of the region.
Asia Pacific is expected to emerge as the fastest growing region with a CAGR of 9.6% over the forecast period. Favourable government initiatives and increasing diagnostic rates are expected to drive the growth of the market in the region.
"Roche to improve market penetration via various product development strategies"
Key players of this market include Abbott Laboratories; Cooper Surgical, Inc.; Becton, Dickinson and Company (BD); Hologic, Inc.; Quest Diagnostics; QIAGEN; Guided Therapeutics; Siemens; OncoHealth Corp.; Arbor Vita; Zilico Ltd.; and Beckman Coulter, Inc. The companies are currently focusing on the technological advancements in the diagnostic techniques, such as liquid-based cytology. In 2014, F. Hoffmann-La Roche Ltd. developed a fully automated CINtec PLUS* cytology test to remove unhealthy tissue from the cervical site before development of cancerous tissue. Moreover, Roche also announced that the company had received a U.S.FDA approval for Avastin, a biologic medicine plus chemotherapy for treating advanced cervical cancer patients.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.